Free Trial

Addus HomeCare (NASDAQ:ADUS) Downgraded to Hold Rating by Wall Street Zen

Addus HomeCare logo with Medical background

Wall Street Zen downgraded shares of Addus HomeCare (NASDAQ:ADUS - Free Report) from a buy rating to a hold rating in a research report report published on Saturday.

A number of other research analysts also recently commented on ADUS. JMP Securities reaffirmed a "market outperform" rating and issued a $150.00 target price on shares of Addus HomeCare in a research report on Friday. Macquarie reaffirmed an "outperform" rating and set a $133.00 price objective on shares of Addus HomeCare in a report on Tuesday, June 10th. Finally, Stephens reissued an "overweight" rating and issued a $142.00 target price on shares of Addus HomeCare in a report on Wednesday, March 12th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $142.57.

Check Out Our Latest Research Report on ADUS

Addus HomeCare Stock Down 1.2%

Addus HomeCare stock traded down $1.37 during midday trading on Friday, reaching $113.79. The company's stock had a trading volume of 195,824 shares, compared to its average volume of 170,637. The company has a market cap of $2.09 billion, a P/E ratio of 25.69, a P/E/G ratio of 1.61 and a beta of 0.81. The company has a quick ratio of 1.74, a current ratio of 1.74 and a debt-to-equity ratio of 0.20. The business has a 50-day simple moving average of $108.91 and a 200-day simple moving average of $111.90. Addus HomeCare has a fifty-two week low of $88.96 and a fifty-two week high of $136.72.

Addus HomeCare (NASDAQ:ADUS - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported $1.42 earnings per share for the quarter, topping the consensus estimate of $1.33 by $0.09. The firm had revenue of $337.71 million during the quarter, compared to analysts' expectations of $341.66 million. Addus HomeCare had a return on equity of 9.23% and a net margin of 6.52%. The firm's revenue was up 20.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.21 earnings per share. On average, research analysts expect that Addus HomeCare will post 4.59 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Addus HomeCare news, EVP Michael D. Wattenbarger sold 2,045 shares of Addus HomeCare stock in a transaction that occurred on Tuesday, May 27th. The stock was sold at an average price of $115.00, for a total value of $235,175.00. Following the transaction, the executive vice president now directly owns 7,796 shares in the company, valued at approximately $896,540. This trade represents a 20.78% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 4.60% of the company's stock.

Institutional Investors Weigh In On Addus HomeCare

Hedge funds have recently modified their holdings of the stock. Natixis raised its position in Addus HomeCare by 111.9% during the 4th quarter. Natixis now owns 250 shares of the company's stock worth $31,000 after buying an additional 132 shares during the last quarter. Smartleaf Asset Management LLC increased its stake in shares of Addus HomeCare by 324.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 280 shares of the company's stock worth $35,000 after acquiring an additional 214 shares during the period. BI Asset Management Fondsmaeglerselskab A S purchased a new position in Addus HomeCare during the first quarter worth about $41,000. Parkside Financial Bank & Trust lifted its position in Addus HomeCare by 38.6% in the fourth quarter. Parkside Financial Bank & Trust now owns 531 shares of the company's stock valued at $67,000 after purchasing an additional 148 shares during the period. Finally, Meeder Asset Management Inc. acquired a new stake in Addus HomeCare in the fourth quarter valued at about $77,000. 95.35% of the stock is owned by institutional investors and hedge funds.

About Addus HomeCare

(Get Free Report)

Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. The company operates through three segments: Personal Care, Hospice, and Home Health.

Featured Articles

Analyst Recommendations for Addus HomeCare (NASDAQ:ADUS)

Should You Invest $1,000 in Addus HomeCare Right Now?

Before you consider Addus HomeCare, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Addus HomeCare wasn't on the list.

While Addus HomeCare currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Congress Bought This Stock at the Bottom—Will You Miss It?
The Drone Industry Is About to 10X—Here’s How to Profit
Why AMD Stock Beats NVIDIA Right Now

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines